Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Oncology Program • Phase 1 open-label trial of PLN-101095 in solid tumors has completed enrollment. PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. The Phase 1 open-label, dose-escalation trial of PLN-101095 as monotherapy and in combination with pembrolizum ...

Exhibit 99.1 The Joint Corp. Reports Third Quarter 2025 Financial Results - Grew Revenue 6%, Compared to Third Quarter 2024 - - Board authorizes an additional $12 million for share repurchases - SCOTTSDALE, Ariz., November 6, 2025 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, posted operating highlights and limited financial information for the quarter ended September 30, 2025. The following figures represent continuing operations unless otherwise st ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3505116 (State or ...

Press Release For Immediate Release Investor Relations Contact: Media Relations Contact: Will Davis Stacey Giglio +1 917-519-6994 +1 321-525-4607 wdavis@gogoair.com sgiglio@gogoair.com Gogo Announces Third Quarter 2025 Results Total Revenue of $223.6 million, up 122% Year-over-Year; Service Revenue of $190.0 million, up 132% Year-over-Year Net Loss of $1.9 million, which includes a $15 million pre-tax acquisition-related earn-out accrual Adjusted EBITDA(1) of $56.2 million, up 61% Year-over-Year Over 200 Ye ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 —————————————————————— FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35897 Voya Financial, Inc. | (Exact name of registrant as specified in its charter) | | | | | --- | --- | --- | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-50175 DORCHESTER MINERALS, L.P. (Exact name of registrant as specified in its charte ...

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results Vancouver, British Columbia (November 6, 2025) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the three and nine months ended September 30, 2025 and provided a summary of r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________________ to ___________________ Commission file number 0-13222 CITIZENS FINANCIAL SERVICES, INC. (Exact name of registrant as specified in its charter) ( ...

Financial Performance - Total net sales for Q3 2025 were $2.73 billion[11] - GAAP net loss for the quarter was $139 million[11] - Adjusted Net Income attributable to common stockholders was $121 million[11] - Adjusted EBITDA for Q3 2025 was $302 million[11] - Adjusted Diluted EPS for the quarter was $0.14[11] Cash and Debt Position - Cash and cash equivalents stood at $2.3 billion[11] - Total debt, excluding finance lease obligations, was $3.1 billion[11] Future Growth Strategy - The company aims for $50 billion in annual revenues within the next decade through acquisitions and organic growth[7] Regulatory and Reporting - The refinancing of Term Loan B is subject to market conditions and no assurances are made regarding its completion[2] - The quarterly report on Form 10-Q for Q3 2025 is expected to be filed on November 6, 2025[3]

loanDepot announces third quarter 2025 financial results Reshaped leadership team focused on capitalizing on loanDepot's unique set of assets to drive operational excellence and profitable market share growth. Positive Q3 momentum from higher revenue and positive operating leverage. Highlights: IRVINE, Calif., November 06, 2025 - loanDepot, Inc. (NYSE: LDI), (together with its subsidiaries, "loanDepot" or the "Company"), today announced results for the third quarter ended September 30, 2025. "A key part of ...